REPLIGEN CORP (RGEN) Free cash flow
- Free cash flow · 12 months (USD): Value $111.97M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $111.97M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $134.86M − $22.90M ≈ $111.97M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $134.86M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 3.25× | Operating cash flow / net income. Period ending 2026-06-30. $134.86M ÷ $41.54M ≈ 3.25× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 134.86M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 22.90M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 111.97M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 41.54M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $111.97M | (m) | $134.86M | $22.90M | (m) | (m) | (m) | $41.54M | (m) | (m) | (m) | 3.25× |
| 2026-03-31 | $106.04M | (m) | $130.71M | $24.67M | (m) | (m) | (m) | $51.40M | (m) | (m) | (m) | 2.54× |
| 2025-12-31 | $93.90M | (m) | $117.42M | $23.52M | (m) | (m) | (m) | $48.89M | (m) | (m) | (m) | 2.40× |
| 2025-09-30 | $109.98M | (m) | $130.89M | $20.91M | (m) | (m) | (m) | $1.74M | (m) | (m) | (m) | 75.31× |
| 2025-06-30 | $108.92M | (m) | $132.11M | $23.19M | (m) | (m) | (m) | $-13.83M | (m) | (m) | (m) | -9.55× |
| 2025-03-31 | $124.80M | (m) | $145.69M | $20.89M | (m) | (m) | (m) | $-22.98M | (m) | (m) | (m) | -6.34× |
| 2024-12-31 | $149.72M | (m) | $175.39M | $25.68M | (m) | (m) | (m) | $-25.51M | (m) | (m) | (m) | -6.87× |
| 2024-09-30 | $134.06M | (m) | $165.28M | $31.22M | (m) | (m) | (m) | $-8.10M | (m) | (m) | (m) | -20.42× |
| 2024-06-30 | $122.57M | (m) | $155.19M | $32.63M | (m) | (m) | (m) | $-1.90M | (m) | (m) | (m) | -81.64× |
| 2024-03-31 | $111.41M | (m) | $147.47M | $36.06M | (m) | (m) | (m) | $14.84M | (m) | (m) | (m) | 9.94× |
| 2023-12-31 | $77.70M | (m) | $113.92M | $36.22M | (m) | (m) | (m) | $41.58M | (m) | (m) | (m) | 2.74× |
| 2023-09-30 | $101.16M | (m) | $146.74M | $45.58M | (m) | (m) | (m) | $115.79M | (m) | (m) | (m) | 1.27× |
| 2023-06-30 | $99.86M | (m) | $148.87M | $49.01M | (m) | (m) | (m) | $138.03M | (m) | (m) | (m) | 1.08× |
| 2023-03-31 | $93.98M | (m) | $160.12M | $66.14M | (m) | (m) | (m) | $167.82M | (m) | (m) | (m) | 0.95× |
| 2022-12-31 | $87.25M | (m) | $172.08M | $84.83M | (m) | (m) | (m) | $185.96M | (m) | (m) | (m) | 0.93× |
| 2022-09-30 | $63.31M | (m) | $159.82M | $96.51M | (m) | (m) | (m) | $166.34M | (m) | (m) | (m) | 0.96× |
| 2022-06-30 | $45.35M | (m) | $140.94M | $95.59M | (m) | (m) | (m) | $159.43M | (m) | (m) | (m) | 0.88× |
| 2022-03-31 | $46.16M | (m) | $132.87M | $86.71M | (m) | (m) | (m) | $145.81M | (m) | (m) | (m) | 0.91× |
| 2021-12-31 | $51.93M | (m) | $119.02M | $67.09M | (m) | (m) | (m) | $128.29M | (m) | (m) | (m) | 0.93× |
| 2021-09-30 | $37.91M | (m) | $84.27M | $46.36M | (m) | (m) | (m) | $118.88M | (m) | (m) | (m) | 0.71× |
| 2021-06-30 | $44.03M | (m) | $83.27M | $39.24M | (m) | (m) | (m) | $99.93M | (m) | (m) | (m) | 0.83× |
| 2021-03-31 | $36.44M | (m) | $62.36M | $25.91M | (m) | (m) | (m) | $79.56M | (m) | (m) | (m) | 0.78× |
| 2020-12-31 | $40.17M | (m) | $62.63M | $22.45M | (m) | (m) | (m) | $59.93M | (m) | (m) | (m) | 1.05× |
| 2020-09-30 | $47.27M | (m) | $65.43M | $18.16M | (m) | (m) | (m) | $43.83M | (m) | (m) | (m) | 1.49× |
| 2020-06-30 | $45.96M | (m) | $65.90M | $19.95M | (m) | (m) | (m) | $30.94M | (m) | (m) | (m) | 2.13× |
| 2020-03-31 | $46.42M | (m) | $66.96M | $20.54M | (m) | (m) | (m) | $23.17M | (m) | (m) | (m) | 2.89× |
| 2019-12-31 | $48.71M | (m) | $67.22M | $18.50M | (m) | (m) | (m) | $21.41M | (m) | (m) | (m) | 3.14× |
| 2019-09-30 | $40.42M | (m) | $55.10M | $14.68M | (m) | (m) | (m) | $23.45M | (m) | (m) | (m) | 2.35× |
| 2019-06-30 | $40.74M | (m) | $52.81M | $12.07M | (m) | (m) | (m) | $26.58M | (m) | (m) | (m) | 1.99× |
| 2019-03-31 | $29.83M | (m) | $40.99M | $11.16M | (m) | (m) | (m) | $21.22M | (m) | (m) | (m) | 1.93× |
| 2018-12-31 | $22.14M | (m) | $32.77M | $10.63M | (m) | (m) | (m) | $16.62M | (m) | (m) | (m) | 1.97× |
| 2018-09-30 | $32.09M | (m) | $42.43M | $10.35M | (m) | (m) | (m) | $23.16M | (m) | (m) | (m) | 1.83× |
| 2018-06-30 | $13.84M | (m) | $21.02M | $7.19M | (m) | (m) | (m) | $23.03M | (m) | (m) | (m) | 0.91× |
| 2018-03-31 | $12.15M | (m) | $17.88M | $5.72M | (m) | $155.48M | (m) | $28.73M | (m) | (m) | 7.82% | 0.62× |
| 2017-12-31 | $12.00M | (m) | $17.45M | $5.45M | (m) | $141.24M | (m) | $28.35M | (m) | (m) | 8.49% | 0.62× |
| 2017-09-30 | $-362.00K | (m) | $4.19M | $4.55M | (m) | $125.22M | (m) | $21.20M | (m) | (m) | -0.29% | 0.20× |
| 2017-06-30 | $-866.00K | (m) | $4.73M | $5.59M | (m) | $113.32M | (m) | $17.69M | (m) | (m) | -0.76% | 0.27× |
| 2017-03-31 | $7.29M | (m) | $12.48M | $5.19M | (m) | $110.04M | (m) | $13.12M | (m) | (m) | 6.63% | 0.95× |
| 2016-12-31 | $3.20M | (m) | $7.52M | $4.33M | (m) | $104.54M | (m) | $11.68M | (m) | (m) | 3.06% | 0.64× |
| 2016-09-30 | $4.88M | (m) | $8.92M | $4.04M | (m) | (m) | (m) | $6.92M | (m) | (m) | (m) | 1.29× |
| 2016-06-30 | $14.40M | (m) | $16.69M | $2.30M | (m) | (m) | (m) | $8.30M | (m) | (m) | (m) | 2.01× |
| 2016-03-31 | $11.76M | (m) | $13.55M | $1.79M | (m) | (m) | (m) | $8.04M | (m) | (m) | (m) | 1.68× |
| 2015-12-31 | $12.43M | (m) | $15.05M | $2.63M | (m) | $83.54M | (m) | $9.35M | (m) | (m) | 14.87% | 1.61× |
| 2015-09-30 | $8.76M | (m) | $13.45M | $4.69M | (m) | $78.48M | (m) | $8.68M | (m) | (m) | 11.16% | 1.55× |
| 2015-06-30 | $7.08M | (m) | $13.19M | $6.12M | (m) | $73.94M | (m) | $7.61M | (m) | (m) | 9.57% | 1.73× |
| 2015-03-31 | $1.82M | (m) | $8.10M | $6.28M | (m) | $68.04M | (m) | $6.82M | (m) | (m) | 2.68% | 1.19× |
| 2014-12-31 | $12.80M | (m) | $18.40M | $5.60M | (m) | $63.55M | (m) | $8.17M | (m) | (m) | 20.14% | 2.25× |
| 2014-09-30 | $20.16M | (m) | $23.99M | $3.82M | (m) | $62.54M | (m) | $11.90M | (m) | (m) | 32.24% | 2.02× |
| 2014-06-30 | $19.11M | (m) | $23.86M | $4.75M | (m) | $66.08M | (m) | $16.32M | (m) | (m) | 28.91% | 1.46× |
| 2014-03-31 | $25.42M | (m) | $30.33M | $4.91M | (m) | $68.04M | (m) | $18.03M | (m) | (m) | 37.37% | 1.68× |
| 2013-12-31 | $21.30M | (m) | $25.93M | $4.63M | (m) | $68.17M | (m) | $16.09M | (m) | (m) | 31.24% | 1.61× |
| 2013-09-30 | $21.61M | (m) | $25.82M | $4.21M | (m) | $71.60M | (m) | $22.32M | (m) | (m) | 30.18% | 1.16× |
| 2013-06-30 | $20.24M | (m) | $22.09M | $1.86M | (m) | $67.88M | (m) | $18.24M | (m) | (m) | 29.81% | 1.21× |
| 2013-03-31 | $13.87M | (m) | $15.30M | $1.43M | (m) | $65.90M | (m) | $15.27M | (m) | (m) | 21.05% | 1.00× |
| 2012-12-31 | $12.18M | (m) | $13.44M | $1.26M | (m) | $62.27M | (m) | $14.16M | (m) | (m) | 19.55% | 0.95× |
| 2012-09-30 | $10.02M | (m) | $11.08M | $1.06M | (m) | $50.62M | (m) | $2.44M | (m) | (m) | 19.80% | 4.54× |
| 2012-06-30 | $7.84M | (m) | $8.76M | $920.97K | (m) | $44.14M | (m) | $1.24M | (m) | (m) | 17.76% | 7.07× |
| 2012-03-31 | $3.31M | (m) | $4.04M | $732.20K | (m) | $36.27M | (m) | $-386.15K | (m) | (m) | 9.13% | -10.47× |
| 2011-12-31 | $2.97M | (m) | $3.75M | $782.14K | (m) | $29.36M | (m) | $-3.64M | (m) | (m) | 10.13% | -1.03× |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $2.71M | (m) | $3.23M | $524.67K | (m) | $27.29M | (m) | $-43.51K | (m) | (m) | 9.92% | -74.28× |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | $-3.05M | (m) | $-2.45M | $597.35K | (m) | $20.97M | (m) | $-4.06M | (m) | (m) | -14.52% | 0.60× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |